Q-omics provides the consensus-scored TMEM159 profile across patient tissues and cancer cell-line models. TMEM159 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM159 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, TMEM159 RNA expression shows 18,837 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where TMEM159 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM159 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM159 survival associations across molecular data types. TMEM159 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM159 RNA expression–survival associations across cancer types. High TMEM159 expression shows unfavorable associations in PAAD, LGG, SCLC and KIRP, but favorable associations in KIRC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM159 RNA expression.
This table summarizes TMEM159 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM159. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM159 shows lower tumor expression in UCEC and higher tumor expression in KIRP, KIRC, LUAD, CHOL and LUSC. The KIRP box plot shows higher TMEM159 RNA expression in tumor versus normal tissue (log2 FC = +1.552, t-test p < 0.001).
This table shows molecular features associated with TMEM159 in patient tissues and cancer cell lines. In patient samples, TMEM159 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM159 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
